Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
Portfolio Pulse from Nabaparna Bhattacharya
BMO Capital Markets analyst Evan David Seigerman reaffirmed an Outperform rating on Merck & Co. with a $132 price target. Merck's acquisition of Caraway Therapeutics, a biotech company focusing on neurodegenerative and rare diseases, is seen as a strategic move to bolster its portfolio ahead of Keytruda's LOE. The $610 million upfront payment for Caraway will be recognized in 4Q23. Seigerman is impressed with Caraway's science and management, and views the acquisition as a positive step for Merck. MRK shares dropped by 0.92% to $101.27.
November 22, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's acquisition of Caraway Therapeutics is viewed positively by BMO Capital Markets, with an Outperform rating and a $132 price target. The deal is expected to enhance Merck's portfolio and address the upcoming Keytruda LOE.
The acquisition of Caraway Therapeutics is likely to be viewed as a positive development for Merck, as it could potentially fill the revenue gap expected from Keytruda's loss of exclusivity. The analyst's positive outlook and the reaffirmed Outperform rating suggest confidence in the company's strategy, which could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100